Is Palantir Stock Overvalued?
By every traditional yardstick, including a price‑to‑sales well above 100,…
Buy
51
CRDF Quote, Financials, Valuation and Earnings
Last price:
$3.82
Seasonality move
:
19.06%
Day range:
$3.67 - $3.87
52-week range:
$2.01 - $5.64
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
344.12x
P/B ratio:
3.58x
Volume:
998.3K
Avg. volume:
960.8K
1-year change:
34.63%
Market cap:
$253.5M
Revenue:
$683K
EPS (TTM):
-$0.92
Analysts' Opinion
-
Consensus RatingCardiff Oncology has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $13.67, Cardiff Oncology has an estimated upside of 258.71% from its current price of $3.81.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing -162.47% downside risk from its current price of $3.81.
Fair Value
-
According to the consensus of 5 analysts, Cardiff Oncology has 258.71% upside to fair value with a price target of $13.67 per share.
CRDF vs. S&P 500
-
Over the past 5 trading days, Cardiff Oncology has underperformed the S&P 500 by -1.42% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cardiff Oncology does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cardiff Oncology revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Cardiff Oncology reported revenues of $109K.
Earnings Growth
-
Cardiff Oncology has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Cardiff Oncology reported earnings per share of -$0.20.
Enterprise value:
173.6M
EV / Invested capital:
2.45x
Price / LTM sales:
344.12x
EV / EBIT:
--
EV / Revenue:
295.20x
PEG ratio (5yr expected):
-1.86x
EV / Free cash flow:
-4.06x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-63.45%
Net Income Margin (TTM):
-8308.5%
Return On Equity:
-77.18%
Return On Invested Capital:
-77.18%
Operating Margin:
-13194.5%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $395K | $610K | $588K | $205K | $109K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$40.9M | -$44.3M | -$52.1M | -$10.9M | -$14.4M | |
| EBITDA | -$40.6M | -$43.7M | -$51.7M | -$10.7M | -$14.2M | |
| Diluted EPS | -$0.89 | -$0.90 | -$0.92 | -$0.22 | -$0.20 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $128.6M | $135.8M | $101.8M | $70M | $82.7M | |
| Total Assets | $129.6M | $139.2M | $106.5M | $74M | $84.8M | |
| Current Liabilities | $4.5M | $6.7M | $8.1M | $11.8M | $13.3M | |
| Total Liabilities | $4.8M | $9.1M | $10M | $13.1M | $13.9M | |
| Total Equity | $124.8M | $130.1M | $96.5M | $60.9M | $70.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$32.2M | -$30M | -$42.7M | -$7.7M | -$12.8M | |
| Cash From Investing | $27.1M | $33.5M | -$5.5M | $4.6M | -$14.6M | |
| Cash From Financing | $75K | $107K | $53.7M | $107K | $3K | |
| Free Cash Flow | -$33.1M | -$30.6M | -$42.7M | -$7.8M | -$12.8M | |
CRDF
Sector
Market Cap
$253.5M
$33.4M
Price % of 52-Week High
67.56%
46.84%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
34.63%
-37.4%
Beta (5-Year)
1.615
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.84
200-day SMA
Buy
Level
$3.24
Bollinger Bands (100)
Buy
Level
2.83 - 4.11
Chaikin Money Flow
Sell
Level
-3.2M
20-day SMA
Buy
Level
$3.41
Relative Strength Index (RSI14)
Buy
Level
61.82
ADX Line
Buy
Level
45.58
Williams %R
Neutral
Level
-42.8571
50-day SMA
Buy
Level
$3.01
MACD (12, 26)
Buy
Level
0.31
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Sell
Level
-7.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.9931)
Sell
CA Score
(Annual)
Level (-1.2913)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (5.2348)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
Stock Forecast FAQ
In the current month, CRDF has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CRDF average analyst price target in the past 3 months is $13.67.
-
Where Will Cardiff Oncology Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cardiff Oncology share price will rise to $13.67 per share over the next 12 months.
-
What Do Analysts Say About Cardiff Oncology?
Analysts are divided on their view about Cardiff Oncology share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cardiff Oncology is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is Cardiff Oncology's Price Target?
The price target for Cardiff Oncology over the next 1-year time period is forecast to be $13.67 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CRDF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cardiff Oncology is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CRDF?
You can purchase shares of Cardiff Oncology via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cardiff Oncology shares.
-
What Is The Cardiff Oncology Share Price Today?
Cardiff Oncology was last trading at $3.82 per share. This represents the most recent stock quote for Cardiff Oncology. Yesterday, Cardiff Oncology closed at $3.81 per share.
-
How To Buy Cardiff Oncology Stock Online?
In order to purchase Cardiff Oncology stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Gamestop’s Bitcoin Strategy Going To Succeed?
When GameStop (NYSE: GME) announced in Q1 that its board had…
How High Will Roku Stock Go?
Streaming software and hardware maker Roku (NASDAQ:ROKU) has seen its…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Sell
11
VEON alert for Jun 14
VEON [VEON] is down 18.57% over the past day.
Buy
74
DAVE alert for Jun 14
Dave [DAVE] is down 12.68% over the past day.
Buy
54
DAR alert for Jun 14
Darling Ingredients [DAR] is up 9.12% over the past day.
